Loading...

Shield Therapeutics plc

STX.L•LSE
Healthcare
Drug Manufacturers - Specialty & Generic
£4.50
£-0.10(-2.17%)

Shield Therapeutics plc (STX.L) Company Profile & Overview

Explore Shield Therapeutics plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Shield Therapeutics plc (STX.L) Company Profile & Overview

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOAnders Lundstrom

Contact Information

https://www.shieldtherapeutics.com
44 1915 118 500
Northern Design Centre, Gateshead, NE8 3DF

Company Facts

63 Employees
IPO DateFeb 26, 2016
CountryGB
Actively Trading

Frequently Asked Questions

;